RecruitingNot ApplicableNCT07400458
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction
Sponsor
Pharmicell Co., Ltd.
Enrollment
100 participants
Start Date
Mar 3, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
Eligibility
Inclusion Criteria2
- Those who had administered Hearticellgram-AMI
- Those who voluntarily agreed in writing to participate in this investigation
Exclusion Criteria1
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALHearticellgram-AMI
Patients who had administered Hearticellgram-AMI.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07400458
Related Trials
SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25)
NCT074925371 location
Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock
NCT051854923 locations
BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
NCT045285115 locations
Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE
NCT063363172 locations
Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease
NCT067882752 locations